Abstract: A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

Abstract: The present invention relates to an amorphous solid dispersion comprising ABX464 and at least one pharmaceutically acceptable carrier. The present invention also concerns a pharmaceutical composition comprising said ASD, processes for their preparation, an ASD obtainable by specific processes, their use as a medicament and more particularly their use in the treatment and/or prevention of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.

Abstract: Co-crystals and pharmaceutically acceptable salts and methods for the preparation of the co-crystals and the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, pharmaceutical compositions including them as well as their use as medicines and more particularly for use in the prevention and/or treatment of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.

Abstract: The present invention relates to polyclonal antibodies for use in the prevention and/or treatment of the Ebola virus disease. In one embodiment, the polyclonal antibodies are specific for a truncated Ebola virus GP glycoprotein. Said polyclonal antibodies are preferably non-human antibodies and are provided in a serum free pharmaceutical composition. The present invention also relates to a method of prevention and/or treatment of Ebola virus disease in a subject in need thereof, comprising administering to said subject polyclonal antibodies specific for the Ebola virus.

Abstract: A system and method for distributing symmetric keys in a system including an end-user computer operated by an end-user, a service provider server of a service provider having a service provider identifier, and a manufacturer backend server operated by the manufacturer of the OTP token. The manufacturer backend server operates to verify one-time passwords generated by the OTP tokens and upon verifying the authenticity of the OTP token based on the generated passwords, transmitting the symmetric key to a service provider server or an authentication server. Other systems and methods are disclosed.

Abstract: A system and method for distributing symmetric keys in a system including an end-user computer operated by an end-user, a service provider server of a service provider having a service provider identifier, and a manufacturer backend server operated by the manufacturer of the OTP token. The manufacturer backend server operates to verify one-time passwords generated by the OTP tokens and upon verifying the authenticity of the OTP token based on the generated passwords, transmitting the symmetric key to a service provider server or an authentication server. Other systems and methods are disclosed.